基于网络医学的梅萨拉用于动脉样硬化治疗的重定位
Jianhui Jiang1, Ziling Zheng1, Chongbo Jiang2
1School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519000, China.
Journal of cardiovascular translational research
|September 10, 2025
概括
梅萨拉是一种治疗炎症性肠病的药物,在治疗动脉样硬化方面具有潜力. 在小鼠模型中,它降低了胆固醇,斑块和肝脂肪,为心血管疾病药物发现提供了新的途径.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 网络医学 网络医学
背景情况:
- 动脉样硬化是全球主要的死亡原因,而他类药物提供了不完整的解决方案.
- 迫切需要新的治疗策略来对抗心血管疾病的进展.
研究的目的:
- 通过网络医学和实验验证,识别新的抗动脉样硬化药物.
- 在动脉样硬化小鼠模型中评估 mesalazine 的疗效,这是一种重新设计的药物.
主要方法:
- 药物预测的综合网络医学方法.
- 在 ApoE-/- 患有动脉样硬化的小鼠体内验证 mesalazine.
- 生物化学分析脂质样本,斑块区域,肝硬化和基因表达.
主要成果:
- 梅萨拉治疗显著降低了总胆固醇,甘油三和LDL-C,同时增加了HDL-C.
- 观察到动脉样硬化斑块区域的显著减少和肝硬化症.
- 通过RT-qPCR证实关键动脉样硬化相关基因的下调.
结论:
- 梅萨拉在临床前模型中显示出显著的抗动脉样硬化作用.
- 通过网络医学重新定位药物,为动脉样硬化治疗提供了一个有希望的策略.
- 梅萨拉具有作为心血管疾病新型治疗剂的潜力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Inflammatory Bowel Disease IV: Pharmacological Management
531
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
531
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
495
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
495
Mesenchymal Stem Cells
5.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439


